Northwestern Medicine | Strategic Alliance Partners

Hiten D. Patel, MD, highlights the background and trial design for the study, “A Prospective Diagnostic Cohort Study to Compare the Accuracy of Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients with Clinically Localized Renal Tumors (BIOPSy)."

"At Northwestern Medicine, we have very extensive and very deep experience with PET-PSMA-based imaging," says Edward M. Schaeffer, MD, PhD.

"Like any test, it's really a very powerful tool. It's just how you deploy the tool," says Edward M. Schaeffer, MD, PhD.

"PSMA PET imaging is used in the initial diagnostic staging and then in subsequent cases where there can be a recurrence after primary treatment.," says Edward M. Schaeffer, MD, PhD.

"PSMA-PET is a radio nucleotide-based imaging modality that really has changed the landscape of how we initially stage and subsequently follow individuals who have a diagnosis of prostate cancer," says Edward M. Schaeffer, MD, PhD.

"We looked at people who were in the intermediate-risk zone, and we found that our calculator did do a better job of helping some of those men avoid unnecessary biopsies," says Adam B. Murphy, MD, MBA, MSCI.

"in general, we can use a simpler regimen [of testosterone replacement therapy] and achieve normal levels," says Peter N. Tsambarlis, MD.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

Researchers sought to understand if a lack of cancer progression as monitored by radiography could substitute overall survival as a metric for metastatic prostate cancer clinical trials.

“The gemcitabine/docetaxel [combination] has been the answer that many people have needed,” says Joshua J. Meeks, MD, PhD.

"When we think about medical fertility preservation, it really is an all-hands-on-deck type of situation," says Kristin Smith, MD.

"I think some of the biggest advances have come in the surgical space," says Vikas Desai, MD.

In this companion article, Jaideep S. Sohi, MD, shares insights on PSMA-PET imaging’s impact on real-world diagnosis and management of prostate cancer.

From a show dog to a family of cats, let's see who some of the top medical professionals are spending their time with when they're not in the clinic.

This monthly series will begin in January 2024, and attendees can earn one category 1 CME credit per session.

“The bladder muscle can get weak as you get older, so developing urinary incontinence or ur-gency is very common as you get older,” says Vikas Desai, MD.

"The genomics assay was using biopsy tissue to help patients make decisions for the treatment choices. We also tested the effect of the assay on provider choice," says Adam B. Murphy, MD, MBA, MSCI.

“Our analysis suggests that there is superior clinical benefit with olaparib versus control both in patients who had and had not received previous taxane treatment,” said Maha Hussain, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

"Specifically when we stratified by tertiles, we saw that at 15 years there was a significant difference in cancer-specific survival for those who had a high MMAI score vs lower MMAI scores," says Eric Li, MD.

"All forms of cancer start out by genetic changes in the DNA that cause cancer, so genetic testing becomes very important," says William J. Catalona, MD.

"We're one of the first to look at hypogonadism, or low testosterone, as a marker for both frailty and also as a biomarker for how these patients do after surgery," says Daniel Greenberg, MD.

"We found that about 25% of these men had either sought treatment for a men's health issue or a sexual issue or had wanted to seek care," says Daniel Greenberg, MD.

“Health literacy pushed people towards active surveillance, which I thought was an interesting finding,” says Adam B. Murphy, MD, MBA, MSCI.

The research projects are assessing combination therapies in advanced prostate cancer that include the use of relugolix.

"For those people in the intervention arm who did get the assay, the doctors were more likely to prefer active treatment with surgery or radiation compared to the control group," says Adam B. Murphy, MD, MBA, MSCI.

“I've always felt like my patients are my partners in discovery,” says Edward M. Schaeffer, MD, PhD.

"It was really wonderful to work with a lot of our coauthors for the chapters because they really are thought leaders in the field," says Edward M. Schaeffer, MD, PhD.

“The purpose of the course is really to bring together like-minded surgeons and physicians who are interested in robotic reconstructive surgery to really come together to not only build a network, but also discuss complex situations, discuss tips and tricks, and also to review the most salient literature in this space,” says Ziho Lee, MD.

“I was of course flattered when Dr. Walsh and Janet Worthington approached me to take the lead on editing and writing this fifth version of the book,” says Edward M. Schaeffer, MD, PhD.